ALPMY Quote, Financials, Valuation and Earnings

Pfizer has a net margin of 7.95% compared to Astellas Pharma's net margin of 25.23%. Astellas Pharma's return on equity of 0.97% beat Pfizer's return on equity of 4.63%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Pfizer has higher upside potential than Astellas Pharma, analysts believe Pfizer is more attractive than Astellas Pharma.

Astellas Pharma has a beta of 0.318, which suggesting that the stock is 68.161% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Astellas Pharma has a quarterly dividend of $0.25 per share corresponding to a yield of 4.81%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Astellas Pharma pays 684.38% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Astellas Pharma quarterly revenues are $3B, which are smaller than Pfizer quarterly revenues of $17.7B. Astellas Pharma's net income of $241.2M is lower than Pfizer's net income of $4.5B. Notably, Astellas Pharma's price-to-earnings ratio is 167.87x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.55x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 7.95% compared to Astellas Pharma's net margin of -5.57%. Astellas Pharma's return on equity of 0.97% beat PeptiDream's return on equity of 34.66%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma has higher upside potential than PeptiDream, analysts believe Astellas Pharma is more attractive than PeptiDream.

Astellas Pharma has a beta of 0.318, which suggesting that the stock is 68.161% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.

Astellas Pharma has a quarterly dividend of $0.25 per share corresponding to a yield of 4.81%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma pays 684.38% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

Astellas Pharma quarterly revenues are $3B, which are larger than PeptiDream quarterly revenues of $36.8M. Astellas Pharma's net income of $241.2M is higher than PeptiDream's net income of -$2.1M. Notably, Astellas Pharma's price-to-earnings ratio is 167.87x while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.55x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 7.95% compared to Astellas Pharma's net margin of 12.96%. Astellas Pharma's return on equity of 0.97% beat Nxera Pharma's return on equity of -5.58%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma has higher upside potential than Nxera Pharma, analysts believe Astellas Pharma is more attractive than Nxera Pharma.

Astellas Pharma has a beta of 0.318, which suggesting that the stock is 68.161% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.345%.

Astellas Pharma has a quarterly dividend of $0.25 per share corresponding to a yield of 4.81%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma pays 684.38% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

Astellas Pharma quarterly revenues are $3B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Astellas Pharma's net income of $241.2M is higher than Nxera Pharma's net income of $8.1M. Notably, Astellas Pharma's price-to-earnings ratio is 167.87x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.55x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 7.95% compared to Astellas Pharma's net margin of 7.83%. Astellas Pharma's return on equity of 0.97% beat Takeda Pharmaceutical's return on equity of 4.01%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 21.44%. Given that Takeda Pharmaceutical has higher upside potential than Astellas Pharma, analysts believe Takeda Pharmaceutical is more attractive than Astellas Pharma.

Astellas Pharma has a beta of 0.318, which suggesting that the stock is 68.161% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.

Astellas Pharma has a quarterly dividend of $0.25 per share corresponding to a yield of 4.81%. Takeda Pharmaceutical offers a yield of 4.72% to investors and pays a quarterly dividend of $0.33 per share. Astellas Pharma pays 684.38% of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Astellas Pharma quarterly revenues are $3B, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Astellas Pharma's net income of $241.2M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Astellas Pharma's price-to-earnings ratio is 167.87x while Takeda Pharmaceutical's PE ratio is 21.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.55x versus 1.38x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.